The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Prostate cancer is the most common cancer in males worldwide. Mass spectrometry‐based targeted proteomics has demonstrated great potential in quantifying proteins from formalin‐fixed paraffin‐embedded (FFPE) and (fresh) frozen biopsy tissues. Here we provide a comprehensive tissue‐specific spectral library for targeted proteomic analysis of prostate tissue samples. Benign and malignant FFPE prostate...
Background and Aims
Recently, clinical trials of lenvatinib plus pembrolizumab in HCC have displayed an impressive objective response rate. This study aimed to clarify the mechanism for optimal patient selection.
Approach and Results
First, in patients with HCC, lenvatinib‐treated recurrent tumors had lower programmed death ligand 1 (PD‐L1) expression and regulatory T cell (Treg) infiltration compared...